论文部分内容阅读
目的:观察沐舒坦雾化吸入治疗老年慢性支气管炎急性发作临床效果。方法:2015年8月至2016年12月,选择此时间段收治的86例老年慢性支气管炎急性发作患者作为研究对象,采用随机信封法将其分为对照组和观察组均43例患者,对照组采用常规治疗措施,观察组在常规治疗的基础上添加沐舒坦雾化吸入治疗,对比两组患者临床指标、并发症发生率。结果:观察组临床指标、并发症发生率明显低于对照组,P<0.05。结论:在老年慢性支气管炎急性发作患者临床治疗中,沐舒坦雾化吸入治疗,既能改善患者临床症状,又可降低并发症发生率,值得临床推广应用。
Objective: To observe the clinical efficacy of mucosolvan inhalation in the treatment of acute episode of senile chronic bronchitis. Methods: From August 2015 to December 2016, 86 patients with acute exacerbation of senile chronic bronchitis were selected as the study subjects, and randomly divided into control group and observation group of 43 patients, control group Group using conventional treatment, the observation group on the basis of conventional treatment with mucosolvan inhalation therapy, compared two groups of patients with clinical indicators, the incidence of complications. Results: The clinical indexes and the incidence of complications in the observation group were significantly lower than those in the control group (P <0.05). Conclusion: In the clinical treatment of patients with acute exacerbation of chronic bronchitis, ambroxol inhalation therapy can not only improve clinical symptoms but also reduce the incidence of complications, which is worthy of clinical application.